126
So grateful to receive the 2022 Johadamis ME/CFS Research Grant! In collaboration with @polybioRF @BjornBragee we will test blood & CSF samples from #MECFS patients for immune phenotypes and antibodies to various pathogens. This will inform us about potential drivers of disease. twitter.com/Tempi_Stiftung…
127
新型コロナ後遺症に関する私たちの研究についてお話しを記事にしていただきました。メカニズムの解析は進んでいますが、さらなる研究と臨床試験が必要です。世界中で苦しんでいる多くの人に役立つ治療に貢献したいです。是非日経サイエンスの特集を読んで下さい👇🏽 #longCOVID
nikkei-science.com/202211_039.html
128
In this new Neuroview in @NeuroCellPress, I discuss "How COVID-19 has transformed my science”. Recounting my personal journey of how I responded to the pandemic, and how the pandemic has transformed the way I do science. Some lessons learned. (1/n)
cell.com/neuron/fulltex…
129
In conclusion, VOCs do not evolve to further escape from CD8 T beyond the ancestral SARS-CoV-2 virus. The virus uses multiple pathways to inhibit MHC I. If one is missing, others compensate. Given this, CD8 T cell-based therapeutic approaches may be difficult for COVID-19. (End)
130
What does this mean? Immune evasion from CD8 T cells could allow infected cells to survive better in the host. The virus could establish a safe niche for prolonged replication. To eliminate such persistent reservoirs, we need to employ antivirals or antibody therapy. (4/)
131
What an honor to be featured in the latest BBC Science in Action with @michelle_monje! We discuss our latest research on how mild respiratory COVID can cause multi-lineage neural dysregulation with @PeaseRoland. Many thanks to @AndrewLuckBaker 🙏🏼
bbc.co.uk/sounds/play/w3…
132
New data are pretty striking. Compared to the ancestral (WA1) or Epsilon (B.1.429) variant, Omicron subvariants BA.1, BA.2.12.1, XAF and BA.4 all suppressed MHC I surface expression better in infected cells. An irrelevant surface marker (CD324) was not affected by infection. (4/)
133
With millions of #longCOVID patients, it is becoming better known that even a mild infection can lead to longterm debilitating health problems. SARS-CoV-2 joins the long list of other pathogens that cause post-acute infection syndrome (PAIS). (2/)
134
I am thrilled to give a talk on “Probing disease mechanisms of long COVID” today. I will highlight many other post acute infection syndromes that lead to ME CFS, and present hypotheses and clues on the pathogenesis of #longCOVID.
deloitte.zoom.us/webinar/regist…
135
We suspect that a subset of #longCOVID patients have viral reservoirs. The reason we use a 15-day trx (not a 5-day used for acute infection) is to allow the drug to eliminate the virus that is causing chronic infection and to remove such reservoirs. (4/)
nature.com/articles/s4159…
136
Seeking candidates for TWO tenure-track assistant/associate positions for @YaleIBIO: one for Section of Human & Translational Immunology and the other one for general immunology. We welcome applicants from diverse backgrounds. Please apply & RT 😊
apply.interfolio.com/99554
137
A more general discussion and powerful testimony by #longCOVID patients can be found in this video by @KnowableMag. I share hypotheses on disease pathogenesis and discuss possible therapies. Please listen to the patients and learn more.
knowablemagazine.org/article/health…
138
To help the parents navigate the COVID vaccines now approved for younger children, I collaborated with Dr. Thomas Murray @YalePediatrics @yalepedsid @ynhhealth to create this table using @BioRender for primary COVID vaccine series for different age groups.
Please share! (1/)
139
So the problem in #longCOVID is not necessarily O2 supply (thus normal cardiopulmonary function) but O2 extraction and thus consumption by tissue. What could cause such defects? Microvascular abnormality? I would love expert input here. @KaminskiMed, @CharleszYaleMed?
140
Consequences of persistent viral RNA may include organ-specific as well as nonspecific postviral syndromes such as long COVID, post-Ebola, and post-polio syndromes, characterized by symptoms including fatigue, headache, muscle pain, and joint pain. (3/)
141
Thank you @ASlavitt for speaking up about #longCOVID 🙏🏼 We need a lot more public attention, research, therapy and drugs to combat this debilitating disease. We also need similar attention/resources/research/treatment for #MECFS that results after infection with other pathogens. twitter.com/ASlavitt/statu…
142
We are now enrolling in the #PaxLCTrial; randomizing people with #longCOVID to 15 days of Paxlovid (nirmatrelvir/ritonavir) or placebo (placebo/ritonavir). Currently people in CT, NY, and FL can enroll. Hope to expand to other states soon. For more info 👉🏼 kindred.hugo.health/pax-lc
143
Congratulations to @FabrizioChiodo and colleagues who worked so hard to develop conjugate vaccine against COVID-19 in Cuba 🇨🇺 Now with [RBD-TT]➡️ [RBD-TT] ➡️ [RBD-RBD] shots, efficacy is 91.2% 👏🏼 👏🏼
Adding this vaccine strategy as another success story in the fight against COVID! twitter.com/FabrizioChiodo…
144
@dianaberrent @DanielGriffinMD I think this is possible, @dianaberrent. A higher viral load exposure will give more opportunity for the virus to replicate robustly in the olfactory mucosa and invade the CNS, after crossing the cribriform plate. This needs to be tested for Delta.
nature.com/articles/s4159…
145
These results indicate that nasal vaccines induce IgA and promote better cross-protective immunity against viral variants, and suggest its utility in combating COVID-19 variants of concern. A great write up by Bill Hathaway. (13/)
news.yale.edu/2021/12/10/nas…
146
First question addressed is WHERE viral RNA can persist. After a variety of RNA virus infection, viral RNA can persist not only in immune privileged sites (brain, eyes, and testes), but also in blood, lymphoid tissue, joints, respiratory tract, GI tissues, and kidney. (2/)
147
This thread is about our new preprint on transposable element called long interspersed nuclear elements (LINE-1/L1). When expressed excessively in the cerebellum, L1 causes ataxia (impaired coordination).
A fascinating finding by @taka_takehiro 👇🏽 (1/)
biorxiv.org/content/10.110…
148
@mocoband @fitterhappierAJ @DrEricDing @EricTopol @DrPatSoonShiong @farid__jalali @dgurdasani1 @jeremyfaust @ToshiAkima @RadCentrism @LeonardiBot @EnemyInAState Thank you @mocoband for sharing. This report adds to a growing evidence of viral persistence in the GI tract, possibly aided by virus shutting down MHC I and evading T cell killing.
biorxiv.org/content/10.110…
149
Latest preprint by @tianyangmao et al shows that a stem-loop RNA RIG-I agonist in mice can
1) Block viral replication and disease when given early after SARS-CoV-2 infection (including VOCs)
2)Eliminate chronic infection in immunodeficient mice
🧵(1/)
biorxiv.org/content/10.110…
150
While we did not test the Delta variant, with its high viral load and transmission capacity, vaccines that induce mucosal immunity (TRM, IgA) may become important to better prevent infection and transmission. (14/n)
news.yale.edu/2021/09/02/imm…
We study innate and adaptive immunity against viruses and study disease pathogenesis. #COVID19 #longCOVID #vaccines @HHMINEWS @YaleIBIO @YaleMed @YaleCII